In this article
On May 14, 2025, the Food and Drug Administration granted accelerated approval for telisotuzumab vedotin-tllv (Emrelis, AbbVie Inc.), a c-Met-targeted antibody and microtubule inhibitor conjugate, for adults with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) exhibiting high c-Met protein overexpression [≥50% of tumor cells with strong (3+) staining], as identified by an FDA-approved assay, who have undergone prior systemic therapy.
The FDA has approved the VENTANA MET (SP44) RxDx Assay (Roche Diagnostics) as a companion diagnostic test to assist in identifying c-Met protein overexpression in individuals with non-squamous NSCLC who may qualify for therapy with Emrelis.
The efficacy was assessed in the LUMINOSITY research (NCT03539536), a multicenter, open-label, multi-cohort investigation. The trial comprised 84 patients with epidermal growth factor receptor (EGFR) wild-type, non-squamous non-small cell lung cancer (NSCLC) exhibiting significant c-Met protein overexpression, all of whom had undergone prior systemic therapy.
The primary efficacy outcome measures were the overall response rate (ORR) and duration of response (DOR), assessed by blinded independent central review (BICR) in accordance with RECIST 1.1. The overall response rate (ORR) was 35% (95% confidence interval: 24, 46), and the median duration of response (DOR) was 7.2 months (95% confidence interval: 4.2, 12).
In a consolidated safety cohort, the predominant adverse events (≥20%) included peripheral neuropathy, tiredness, diminished appetite, and peripheral edema. The prevalent Grade 3 or 4 laboratory abnormalities (≥2%) included reduced lymphocytes, elevated glucose, increased alanine aminotransferase, heightened gamma glutamyl transferase, diminished phosphorus, decreased sodium, lowered hemoglobin, and decreased calcium.
The advised dosage of telisotuzumab vedotin-tllv is 1.9 mg/kg (capped at 190 mg for patients weighing ≥100 kg), administered as an intravenous infusion biweekly, unless disease progression or intolerable toxicity occurs.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.